Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Rudzki

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Hematology|April 19, 2011
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Jakob Rudzki, Dominik Wolf
Memo|January 1, 2019
ASCO 2018 NSCLC highlights-combination therapy is keyGabriele Gamerith, Florian Kocher, Jakob Rudzki, et al.
Cancers|September 9, 2022
Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)Tina Künz, Alexander W Hauswirth, Gabriele Hetzenauer, et al.
Cancers|September 28, 2021
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and BeyondIrene Strassl, Martin Schreder, Normann Steiner, et al.
The Journal of Biological Chemistry|November 14, 2001
ICln ion channel splice variants in Caenorhabditis elegans: voltage dependence and interaction with an operon partner proteinJohannes Fürst, Markus Ritter, Jakob Rudzki, et al.
Cancers|February 11, 2023
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational StudyNormann Steiner, Georg Göbel, Leonie Mauser, et al.
Transplantation and Cellular Therapy|April 19, 2026
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphomaStefan Koeck, Natalia Rotter, Olga Stiefel, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Hematology|April 19, 2011
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Jakob Rudzki, Dominik Wolf
Memo|January 1, 2019
ASCO 2018 NSCLC highlights-combination therapy is keyGabriele Gamerith, Florian Kocher, Jakob Rudzki, et al.
Cancers|September 9, 2022
Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)Tina Künz, Alexander W Hauswirth, Gabriele Hetzenauer, et al.
Cancers|September 28, 2021
The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and BeyondIrene Strassl, Martin Schreder, Normann Steiner, et al.
The Journal of Biological Chemistry|November 14, 2001
ICln ion channel splice variants in Caenorhabditis elegans: voltage dependence and interaction with an operon partner proteinJohannes Fürst, Markus Ritter, Jakob Rudzki, et al.
Cancers|February 11, 2023
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational StudyNormann Steiner, Georg Göbel, Leonie Mauser, et al.
Transplantation and Cellular Therapy|April 19, 2026
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphomaStefan Koeck, Natalia Rotter, Olga Stiefel, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Pageof 1